{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-122387","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.408272+00:00","generated_at":"2026-05-29T18:47:23.203572+00:00","sec_items":["2.02","5.07","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio appoints David Arkowitz and António Parada as independent directors","bullets":["David Arkowitz (Alkeus Pharma CFO) and António Parada (FairJourney Biologics CEO) join board effective Nov 25, 2024.","Arkowitz brings financial expertise; Parada adds antibody discovery depth; CEO cites alignment with next-gen strategy.","Departing director General Tom Hill thanked for 16 years of service; board now three Class I directors.","Annual meeting on Nov 21 passed all proposals: elected three directors, ratified Grassi & Co., and approved say-on-pay."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-122387","json":"https://secwatch.observer/filing/0001104659-24-122387.json","markdown":"https://secwatch.observer/filing/0001104659-24-122387.md","text":"https://secwatch.observer/filing/0001104659-24-122387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000110465924122387/0001104659-24-122387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000110465924122387/tm2429233d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:47:23.203572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}